Chinese biotech company Sironax and OriCell Therapeutics (Shanghai) have announced the completion of their Series B financing rounds.
Sironax raises $200m Series B
China’s biotech company Sironax has raised $200 million in a Series B funding round led by Gaorong Capital and Yunfeng Capital, according to an announcement.
New investors in the round include MSA Capital, CBC Group, Long River Investments, LSV Capital, Superstring Capital, and Future Innovation Fund as well as a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA).
Existing investors including Temasek, Invus, F-Prime Capital, Eight Roads, ARCH Venture Partners, K2 Venture Partners and others participated in this round.
With this, the company has raised over $300 million to date.
Sironax plans to use the proceeds to support the clinical development of its portfolio and the expansion of its R&D footprint.
Qiming leads $120m Series B round in OriCell Therapeutics
OriCell Therapeutics (Shanghai) (OriCell) has completed its $120-million Series B round jointly led by Qiming Venture Partners and Quan Capital. Several international and Chinese investment funds, as well as existing shareholder C&D Emerging Capital joined the round.
The firm will use the proceeds to develop its cell therapy pipeline, proprietary discovery platform, as well as the construction of a manufacturing plant for both clinical and commercial purposes.
Founded in 2015, OriCell Therapeutics aims to develop novel immunotherapies to satisfy globally unmet clinical needs.
Chinese venture capital firm Qiming Venture Partners secured $3.2 billion in capital commitments from the close of its latest funds